Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Director comp.
Director departure

REVELATION BIOSCIENCES, INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/02/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
10/02/2023 8-K Quarterly results
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/28/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 San Diego, CA – August 11, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash ..."
08/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/14/2023 8-K Quarterly results
07/07/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/07/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: ". If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date and time as may be determined from time to time by the Board of Directors of the Corporation . The meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine. Any other proper business may be transacted at the annual meeting."
06/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders San Diego, CA – June 29, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges all stockholders to vote now. YOUR VOTE IS IMPORTANT - NO MATTER HOW MANY SHARES YOU OWN, HOW FEW SHARES YOU OWN, OR IF YOU VOTE YOUR SHARES FOR, AGAINST OR ABSTAIN Important Information This communication may be deemed to be solicitation material in connection with the proposals to be considered at the Annual Meeting. In connection with..."
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/25/2023 8-K Investor presentation
Docs: "DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084"
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/03/2023 8-K Quarterly results
Docs: "Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress San Diego, CA – March 30, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its year end 2022 financial results and highlighted recent corporate progress. Corporate Highlights • Completed a $15.6 million public offering. • Announced additional positive biomarker data from a preclinical study of REVTx-300 in acute kidney injury and chronic kidney disease. • Anticipates starting the combined Phase 1a clinical study for RETx-100 and REVTx-300. “We are hopeful for a great 2023, starting with ..."
02/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/28/2023 4 Rolke James (CEO) has filed a Form 4 on REVELATION BIOSCIENCES, INC.
Txns: Granted 2,542 options to buy @ $49, valued at $124.6k
02/14/2023 SC 13G AXA IM Prime Impact Master Fund I SCA SICAV-RAIF reports a 8.3% stake in Revelation Biosciences, Inc.
02/14/2023 5 AXA IM Prime Impact Master Fund I SCA SICAV-RAIF (Former 10% Owner) has filed a Form 5 on REVELATION BIOSCIENCES, INC.
02/13/2023 8-K Quarterly results
02/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/09/2023 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
02/09/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy